{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:52:48Z","timestamp":1790283168056,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T00:00:00Z","timestamp":1426204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T00:00:00Z","timestamp":1426204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer progression involves carcinogenesis, an increase in tumour size and metastasis. Here, we investigated the effect of overexpressed CXC chemokine ligand 14 (CXCL14) on these processes by using CXCL14\/BRAK (CXCL14) transgenic (Tg) mice. The rate of AOM\/DSS-induced colorectal carcinogenesis in these mice was significantly lower compared with that for isogenic wild type C57BL\/6 (Wt) mice. When tumour cells were injected into these mice, the size of the tumours that developed and the number of metastatic nodules in the lungs of the animals were always significantly lower in the Tg mice than in the Wt ones. Injection of anti-asialo-GM1 antibodies to the mice before and after injection of tumour cells attenuated the suppressing effects of CXCL14 on the tumor growth and metastasis, suggesting that NK cell activity played an important role during CXCL14-mediated suppression of tumour growth and metastasis. The importance of NK cells on the metastasis was also supported when CXCL14 was expressed in B16 melanoma cells. Further, the survival rates after tumour cell injection were significantly increased for the Tg mice. As these Tg mice showed no obvious abnormality, we propose that CXCL14 to be a promising molecular target for cancer suppression\/prevention.<\/jats:p>","DOI":"10.1038\/srep09083","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T10:09:31Z","timestamp":1426241371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Suppressed rate of carcinogenesis and decreases in tumour volume and lung metastasis in CXCL14\/BRAK transgenic mice"],"prefix":"10.1038","volume":"5","author":[{"given":"Ryu-Ichiro","family":"Hata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Izukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumasa","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naofumi","family":"Mukaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yojiro","family":"Maehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Akasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Kiyono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,13]]},"reference":[{"key":"BFsrep09083_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/sj.bjc.6601256","volume":"89","author":"MV Blagosklonny","year":"2003","unstructured":"Blagosklonny, M. V. Tissue-selective therapy of cancer. Br J Cancer 89, 1147\u20131151 (2003).","journal-title":"Br J Cancer"},{"key":"BFsrep09083_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture, M. E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6, 803\u2013812 (2006).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep09083_CR3","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nrc1950","volume":"6","author":"SM Bentzen","year":"2006","unstructured":"Bentzen, S. M. Preventing or reducing late side effects of radiation therapy: radiology meets molecular pathology. Nat Rev Cancer 6, 702\u2013713 (2006).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep09083_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1471-2407-12-161","volume":"12","author":"R Gu","year":"2012","unstructured":"Gu, R. et al. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study. BMC Cancer 12, 161 (2012).","journal-title":"BMC Cancer"},{"key":"BFsrep09083_CR5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/nrc2008","volume":"6","author":"E Szabo","year":"2006","unstructured":"Szabo, E. Selecting targets for cancer prevention: where do we go from here? Nat Rev Cancer 6, 867\u2013874 (2006).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep09083_CR6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrc3397","volume":"12","author":"A Umar","year":"2012","unstructured":"Umar, A., Dunn, B. K. & Greenwald, P. Future directions in cancer prevention. Nat Rev Cancer 12, 835\u2013848 (2012).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep09083_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nrc2663","volume":"9","author":"TG Cotter","year":"2009","unstructured":"Cotter, T. G. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 9, 501\u2013507 (2009).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep09083_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/35094059","volume":"1","author":"MJ Bissell","year":"2001","unstructured":"Bissell, M. J. & Radisky, D. Putting tumours in context. Nat Rev Cancer 1, 46\u201354 (2001).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep09083_CR9","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat Med 19, 1423\u20131437 (2013).","journal-title":"Nat Med"},{"key":"BFsrep09083_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1006\/bbrc.1999.0257","volume":"255","author":"R Hromas","year":"1999","unstructured":"Hromas, R. et al. Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun 255, 703\u2013706 (1999).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep09083_CR11","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0002-9440(10)65067-5","volume":"156","author":"MJ Frederick","year":"2000","unstructured":"Frederick, M. J. et al. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 156, 1937\u20131950 (2000).","journal-title":"Am J Pathol"},{"key":"BFsrep09083_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/gb-2006-7-12-243","volume":"7","author":"A Zlotnik","year":"2006","unstructured":"Zlotnik, A., Yoshie, O. & Nomiyama, H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 7, 243 (2006).","journal-title":"Genome Biol"},{"key":"BFsrep09083_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc1388","volume":"4","author":"F Balkwill","year":"2004","unstructured":"Balkwill, F. Cancer and the chemokine network. Nat Rev Cancer 4, 540\u2013550 (2004).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep09083_CR14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1189\/jlb.1105633","volume":"79","author":"T Kakinuma","year":"2006","unstructured":"Kakinuma, T. & Hwang, S. T. Chemokines, chemokine receptors and cancer metastasis. J Leukoc Biol 79, 639\u2013651 (2006).","journal-title":"J Leukoc Biol"},{"key":"BFsrep09083_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.canlet.2007.05.013","volume":"256","author":"D Raman","year":"2007","unstructured":"Raman, D., Baugher, P. J., Thu, Y. M. & Richmond, A. Role of chemokines in tumor growth. Cancer Lett 256, 137\u2013165 (2007).","journal-title":"Cancer Lett"},{"key":"BFsrep09083_CR16","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/j.1349-7006.2007.00606.x","volume":"98","author":"K Koizumi","year":"2007","unstructured":"Koizumi, K., Hojo, S., Akashi, T., Yasumoto, K. & Saiki, I. Chemokine receptor in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 98, 1652\u20131658 (2007).","journal-title":"Cancer Sci"},{"key":"BFsrep09083_CR17","doi-asserted-by":"publisher","first-page":"797619","DOI":"10.5402\/2012\/797619","volume":"2012","author":"R Hata","year":"2012","unstructured":"Hata, R. A new strategy to find targets for anticancer therapy: Chemokine CXCL14\/BRAK is a multifunctional tumor suppressor for head and neck squamous cell carcinoma. ISRN Otolaryngol 2012, 797619 (2012).","journal-title":"ISRN Otolaryngol"},{"key":"BFsrep09083_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.bbrc.2006.07.070","volume":"348","author":"S Ozawa","year":"2006","unstructured":"Ozawa, S. et al. BRAK\/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochem Biophys Res Commun 348, 406\u2013412 (2006).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep09083_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2220\/biomedres.30.315","volume":"30","author":"S Ozawa","year":"2009","unstructured":"Ozawa, S., Kato, Y., Kubota, E. & Hata, R. BRAK\/CXCL14 expression in oral carcinoma cells completely suppresses tumor cell xenografts in SCID mouse. Biomed Res 30, 315\u2013318 (2009).","journal-title":"Biomed Res"},{"key":"BFsrep09083_CR20","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1111\/j.1349-7006.2009.01281.x","volume":"100","author":"S Ozawa","year":"2009","unstructured":"Ozawa, S. et al. Restoration of BRAK\/CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma. Cancer Sci 100, 2202\u20132209 (2009).","journal-title":"Cancer Sci"},{"key":"BFsrep09083_CR21","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s11248-010-9384-7","volume":"19","author":"K Izukuri","year":"2010","unstructured":"Izukuri, K. et al. Chemokine CXCL14\/BRAK transgenic mice suppress growth of carcinoma cell transplants. Transgenic Res 19, 1109\u20131117 (2010).","journal-title":"Transgenic Res"},{"key":"BFsrep09083_CR22","first-page":"4217","volume":"44","author":"E Farber","year":"1984","unstructured":"Farber, E. The multistep nature of cancer development. Cancer Res 44, 4217\u20134223 (1984).","journal-title":"Cancer Res"},{"key":"BFsrep09083_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/0168-9525(93)90209-Z","volume":"9","author":"B Vogelstein","year":"1993","unstructured":"Vogelstein, B. & Kinzler, K. W. The multistep nature of cancer. Trends Genet 9, 138\u2013141 (1993).","journal-title":"Trends Genet"},{"key":"BFsrep09083_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).","journal-title":"Cell"},{"key":"BFsrep09083_CR25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1309\/LMQOXCQEF7ZXIIUK","volume":"41","author":"K Izukuri","year":"2010","unstructured":"Izukuri, K. et al. Determination of serum BRAK\/CXCL14 levels in healthy volunteers. Lab Medicine 41, 478\u2013482 (2010).","journal-title":"Lab Medicine"},{"key":"BFsrep09083_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/carcin\/bgn267","volume":"30","author":"DW Rosenberg","year":"2009","unstructured":"Rosenberg, D. W., Giardina, C. & Tanaka, T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 30,183\u2013196 (2009).","journal-title":"Carcinogenesis"},{"key":"BFsrep09083_CR27","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/carcin\/bgt377","volume":"35","author":"D Hirsh","year":"2014","unstructured":"Hirsh, D. et al. LGR5 positivity defines stem-like cells in colorectal cancer. Carcinogenesis 35, 849\u2013858 (2014).","journal-title":"Carcinogenesis"},{"key":"BFsrep09083_CR28","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1349-7006.2006.00257.x","volume":"97","author":"K Seino","year":"2006","unstructured":"Seino, K., Motohashi, S., Fujisawa, T., Nakayama, T. & Taniguchi, M. Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci 97, 807\u2013812 (2006).","journal-title":"Cancer Sci"},{"key":"BFsrep09083_CR29","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1182\/blood.V99.4.1259","volume":"99","author":"MJ Smyth","year":"2002","unstructured":"Smyth, M. J. et al. Sequential production of interferon-gamma by NK1.1 (+) T cells and natural killer cells is essential for the antimetastatic effect of \u03b1-galactosylceramide. Blood 99, 1259\u20131266 (2002).","journal-title":"Blood"},{"key":"BFsrep09083_CR30","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.exphem.2006.05.015","volume":"34","author":"T Starnes","year":"2006","unstructured":"Starnes, T. et al. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exptl Hematol 34, 1101\u20131105 (2006).","journal-title":"Exptl Hematol"},{"key":"BFsrep09083_CR31","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/j.1349-7006.1999.tb00818.x","volume":"90","author":"M Nakui","year":"1999","unstructured":"Nakui, M. et al. Natural killer T cell ligand alpha-galactosylceramide inhibited lymph node metastasis of highly metastatic melanoma cells. Jpn J Cancer Res 90, 801\u2013804 (1999).","journal-title":"Jpn J Cancer Res"},{"key":"BFsrep09083_CR32","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1189\/jlb.0411208","volume":"90","author":"K Takeda","year":"2011","unstructured":"Takeda, K. et al. IFN-\u03b3 production by lung NK cells is a critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J. Leukoc Biol 90, 777\u2013785 (2011).","journal-title":"J. Leukoc Biol"},{"key":"BFsrep09083_CR33","doi-asserted-by":"publisher","first-page":"8262","DOI":"10.1158\/0008-5472.CAN-04-2056","volume":"64","author":"TD Shellenberger","year":"2004","unstructured":"Shellenberger, T. D. et al. BRAK\/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res 64, 8262\u20138270 (2004).","journal-title":"Cancer Res"},{"key":"BFsrep09083_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2220\/biomedres.31.199","volume":"31","author":"S Ito","year":"2010","unstructured":"Ito, S. et al. Expression of a chemokine BRAK\/CXCL14 in oral floor carcinoma cells reduces the settlement rate of the cells and suppresses their proliferation in vivo. Biomed Res 31, 199\u2013206 (2010).","journal-title":"Biomed Res"},{"key":"BFsrep09083_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M Paez-Ribes","year":"2009","unstructured":"Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220\u2013231 (2009).","journal-title":"Cancer Cell"},{"key":"BFsrep09083_CR36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","volume":"15","author":"JML Ebos","year":"2009","unstructured":"Ebos, J. M. L. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232\u2013239 (2009).","journal-title":"Cancer Cell"},{"key":"BFsrep09083_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccr.2009.02.007","volume":"15","author":"S Loges","year":"2009","unstructured":"Loges, S., Mazzone, M., Hohensinner, P. & Carmeliet, P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15, 167\u2013170 (2009).","journal-title":"Cancer Cell"},{"key":"BFsrep09083_CR38","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.febslet.2013.04.046","volume":"587","author":"K Tanegashima","year":"2013","unstructured":"Tanegashima, K. et al. CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis. FEBS Lett 587, 1731\u20131735 (2013).","journal-title":"FEBS Lett"},{"key":"BFsrep09083_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1515\/bmc-2014-0007","volume":"5","author":"T Hara","year":"2014","unstructured":"Hara, T. & Tanegashima K. CXCL14 antagonizes the CXCL12-CXCR4 signaling axis. BioMol Concepts 5, 167\u2013173 (2014).","journal-title":"BioMol Concepts"},{"key":"BFsrep09083_CR40","first-page":"1347","volume":"6","author":"M Cojoc","year":"2013","unstructured":"Cojoc, M. et al. Emerging targets in cancer management: role of the CXCL12\/CXCR4 axis. Onco Targets Therapy 6, 1347\u20131361 (2013).","journal-title":"Onco Targets Therapy"},{"key":"BFsrep09083_CR41","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1158\/0008-5472.CAN-05-3393","volume":"66","author":"K Yasumoto","year":"2006","unstructured":"Yasumoto, K. et al. Role of the CXCL12\/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res 66, 2181\u20132187 (2006).","journal-title":"Cancer Res"},{"key":"BFsrep09083_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature12681","volume":"505","author":"BS Ding","year":"2014","unstructured":"Ding, B. S. et al. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature 505, 97\u2013102 (2014).","journal-title":"Nature"},{"key":"BFsrep09083_CR43","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.4049\/jimmunol.0900525","volume":"184","author":"L Chen","year":"2010","unstructured":"Chen, L. et al. Overexpression of CXC chemokine ligand 14 exacerbates collagen-induced arthritis. J Immunol 184, 4455\u20134459 (2010).","journal-title":"J Immunol"},{"key":"BFsrep09083_CR44","first-page":"305","volume":"65","author":"R Holmdahl","year":"1988","unstructured":"Holmdahl, R., Jansson, L., Andersson, M. & Larsson, E. Immunogenetics of type II collagen autoimmunity and susceptibility to collagen arthritis. Immunology 65, 305\u2013310 (1988).","journal-title":"Immunology"},{"key":"BFsrep09083_CR45","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.cyto.2008.08.009","volume":"44","author":"S Meuter","year":"2008","unstructured":"Meuter, S. & Moser, B. Constitutive expression of CXCL14 in healthy human and murine epithelial tissues. Cytokine 44, 248\u2013255 (2008).","journal-title":"Cytokine"},{"key":"BFsrep09083_CR46","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1158\/0008-5472.CAN-10-0427","volume":"70","author":"EY Song","year":"2010","unstructured":"Song, E. Y., Shurin, M. R., Tourkova, I. L., Gutkin, D. W. & Shurin, G. V. Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells. Cancer Res 70, 4394\u20134401 (2010).","journal-title":"Cancer Res"},{"key":"BFsrep09083_CR47","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.1038\/onc.2010.255","volume":"29","author":"M Tessema","year":"2010","unstructured":"Tessema, M. et al. Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene 29, 5159\u20135170 (2010).","journal-title":"Oncogene"},{"key":"BFsrep09083_CR48","first-page":"137","volume":"16","author":"B Cao","year":"2013","unstructured":"Cao, B. et al. Epigenetic silencing of CXCL14 induced colorectal cancer migration and invasion. Discovery Medicine 16, 137\u2013147 (2013).","journal-title":"Discovery Medicine"},{"key":"BFsrep09083_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/pros.20215","volume":"64","author":"SR Schwarze","year":"2005","unstructured":"Schwarze, S. R., Luo, J., Isaacs, W. B. & Jarrard, D. F. Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 64, 67\u201374 (2005).","journal-title":"Prostate"},{"key":"BFsrep09083_CR50","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1165\/rcmb.2012-0396OC","volume":"49","author":"R Shaykhiev","year":"2013","unstructured":"Shaykhiev, R. et al. Smoking-induced CXCL14 expression in the human airway epithelium links chronic obstructive pulmonary disease to lung cancer. Am J Respir Cell Mol Biol 49, 418\u2013425 (2013).","journal-title":"Am J Respir Cell Mol Biol"},{"key":"BFsrep09083_CR51","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1479-5876-11-6","volume":"11","author":"J Zeng","year":"2013","unstructured":"Zeng, J. et al. Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection. J Transl Med 11, 6 (2013).","journal-title":"J Transl Med"},{"key":"BFsrep09083_CR52","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1073\/pnas.0813144106","volume":"106","author":"M Augsten","year":"2009","unstructured":"Augsten, M. et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci U S A 106, 3414\u20133419 (2009).","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BFsrep09083_CR53","doi-asserted-by":"publisher","first-page":"9276","DOI":"10.1158\/0008-5472.CAN-07-2124","volume":"67","author":"Y Zhao","year":"2007","unstructured":"Zhao, Y. et al. Cancer resistance in transgenic mice expressing the SAC module of Par-4. Cancer Res 67, 9276\u20139285 (2007).","journal-title":"Cancer Res"},{"key":"BFsrep09083_CR54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cell.2012.02.030","volume":"149","author":"I Garcia-Cao","year":"2012","unstructured":"Garcia-Cao, I. et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 149, 49\u201362 (2012).","journal-title":"Cell"},{"key":"BFsrep09083_CR55","doi-asserted-by":"publisher","first-page":"7884","DOI":"10.1158\/0008-5472.CAN-09-1451","volume":"69","author":"BK Popivanova","year":"2009","unstructured":"Popivanova, B. K. et al. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res 69, 7884\u20137892 (2009).","journal-title":"Cancer Res"},{"key":"BFsrep09083_CR56","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/ijc.28779","volume":"135","author":"S Sasaki","year":"2014","unstructured":"Sasaki, S., Baba, T., Shinagawa, K., Matsushima, K. & Mukaida N. Crucial involvement of the CCL3-CCR5 axis-mediated fibroblast accumulation in colitis-associated carcinogenesis in mice. Int. J. Cancer 135, 1297\u20131306 (2014).","journal-title":"Int. J. Cancer"},{"key":"BFsrep09083_CR57","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2220\/biomedres.31.123","volume":"31","author":"R Komori","year":"2010","unstructured":"Komori, R. et al. Functional characterization of proximal promoter of gene for human BRAK\/CXCL14, tumor-suppressing chemokine. Biomed Res 31, 123\u2013131 (2010).","journal-title":"Biomed Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep09083","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep09083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep09083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T16:22:15Z","timestamp":1672935735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep09083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,13]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,8,14]]}},"alternative-id":["BFsrep09083"],"URL":"https:\/\/doi.org\/10.1038\/srep09083","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,13]]},"assertion":[{"value":"12 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9083"}}